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Abstract
Knowledge discovery from omics data has become a common goal of cur-
rent approaches to personalised cancer medicine and understanding cancer
genotype and phenotype. However, high-throughput biomedical datasets are
characterised by high dimensionality and relatively small sample sizes with
small signal-to-noise ratios. Extracting and interpreting relevant knowledge
from such complex datasets therefore remains a significant challenge for the
fields of machine learning and data mining. In this paper, we exploit recent
advances in deep learning to mitigate against these limitations on the ba-
sis of automatically capturing enough of the meaningful abstractions latent
with the available biological samples. Our deep feature learning model is
proposed based on a set of non-linear sparse Auto-Encoders that are deliber-
ately constructed in an under-complete manner to detect a small proportion
of molecules that can recover a large proportion of variations underlying
the data. However, since multiple projections are applied to the input sig-
nals, it is hard to interpret which phenotypes were responsible for deriving
such predictions. Therefore, we also introduce a novel weight interpretation
technique that helps to deconstruct the internal state of such deep learning
models to reveal key determinants underlying its latent representations. The
outcomes of our experiment provide strong evidence that the proposed deep
mining model is able to discover robust biomarkers that are positively and
negatively associated with cancers of interest. Since our deep mining model
is problem-independent and data-driven, it provides further potential for this
research to extend beyond its cognate disciplines.
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1. Introduction
Advances in molecular sciences have led to an exponential growth in vol-
ume, variety, and complexity of biological information. As a result, diverse
types of high-throughput omics data have been provided such as genomic,
transcriptomic, proteomic and metabolomic. Current omics data analysis
approaches aim for deriving relevant knowledge from such datasets for an-
swering serious etiologic questions about cancer and developing effective pro-
cedures to prevent, detect, manage, and treat this heterogeneous complicated
disease. The knowledge domain addressed by this omics data analysis re-
search is that of clinically relevant ‘biomarkers’ for cancers of interest. A
biomarker is formally defined as “a biological characteristic that is objec-
tively measured and evaluated as an indicator of normal biologic processes,
pathogenic processes, or pharmacologic responses to a therapeutic interven-
tion” [1]. Biomarker identification from omics data has become a key goal to
approach precision medicine that aims to exploit the explosion of molecular
data together with individual patient characteristics to optimise therapeutic
benefits [2]. Therefore, the next frontier in the move towards personalised
cancer medicine is to develop sophisticated knowledge discovery models that
can detect molecular markers that could act as risk factors for cancer and un-
derlie the variations of control (i.e. individuals without disease) and cancer
(i.e. individuals with disease) groups.
Omics datasets are characterised by high dimensionality, complexity, rel-
atively small sample sizes and the amount of noise. These characteristics
have significantly challenged traditional statistical techniques and machine
learning methods due to a range of subsequent issues such as the curse of di-
mensionality, bias-variance trade-off, model robustness, interpretability and
computational cost. This has motivated the development of more sophisti-
cated feature mining models to support knowledge extraction for prediction
purposes, which has become a core process in the construction of high dimen-
sional biomedical data classification models. However, omics data has the
additional problem of small sample sizes such that the number of variables
vastly exceeds the number of observations putting even more pressure on
data mining methods for extracting relevant, robust and reproducible molec-
ular markers. This is evidenced by the limited success these methods have
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had in detecting robust and reliable biomarkers for cancers and other compli-
cated diseases. This could also explain why the discovery of true biomarkers
from omics data remains a major challenge, and illustrate the lack of finding
generic biomarkers among the identified published genes for identical diseases
or clinical conditions. As a result, the problem of biomarker discovery from
High Dimensional Small Sample Size (HDSSS) omics data is complicated and
requires more sophisticated mining models that can address these challenging
issues and infer useful knowledge from human molecular data for modelling
reliable prediction systems.
The research interest has recently transformed towards feature learning
algorithms for discovering useful knowledge from the raw high dimensional
data without the need for hand designed features that require domain exper-
tise or ad-hoc specific methodologies and techniques. The question is what
are the required elements of a feature learning algorithm to be able to exploit
large and noisy spaces of omics data effectively and discover robust biomark-
ers? Given the fact that omics data are more likely to be non-linear in nature
[3], there is a necessity for nonlinear feature learning that avoids the linear
assumptions of traditional statistical techniques in order to discover enough
of the meaningful intricacies underlying these high-throughput biomedical
data. Since it has been shown that learning models with a single stage of
input transformation (i.e. shallow) can lead to poor levels of generalisation
unless a huge number of samples and resources are provided [4], therefore,
there is a significant requirement for feature learning based on deep architec-
tures. Shallow architectures are more likely to capture low-level features of
the input, encoding more noise, and lacking the variance in training data to
constrain the weights and thus representations. With deep architectures, the
dimensionality can be substantially reduced, thus the problem can be further
abstracted by learning high-level abstract features from low-level represen-
tations, allowing better generalisation performance and knowledge transfer
[5, 6]. This necessitates the need for deep feature learning models that con-
sist of multiple levels of input transformation of increasing abstractions in
order to mitigate against the curse of dimensionality of omics data.
Knowledge discovery from omics data has the additional challenge of small
sample sizes such that the number of features is much greater than the num-
ber of samples. For a small training set, it has been shown that deep feature
learning based on an unsupervised pre-training approach produces consis-
tently better generalisation performance and prevents the risk of overfitting
[7]. Therefore, the unsupervised pre-training approach is considered in this
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research as an essential characteristic of the deep non-linear feature learn-
ing model to be able to exploit more subtle patterns in HDSSS omics data.
However, as discussed previously, the dimensionality of omics data is high
(i.e. tens of thousands of molecules), and that means, there is an exponential
number of possible input configurations. Therefore, the available biological
samples become even increasingly sparse making the process of discovering
plausible and robust input configurations a very difficult task. Moreover,
in genomic datasets, very few genes are expressed reliably at biologically
significant levels and distinguishably from noise and measurement variation
[8]. Consequently, a new feature learning model is introduced based on a
set of non-linear sparse Auto-Encoders that are deliberately constructed in
an under-complete manner to force the network to find progressively the
complex featural representations necessary to capture enough of the impor-
tant variations underlying the biological samples. The proposed deep feature
learning model is utilised to discover and interpret important signals from
omics data that aid prediction relevant to precision medicine.
The proposed deep feature learning model applies multiple levels of pro-
jections to the input features to abstract the problem and capture high-level
dependencies for achieving a high-level of generalisability. This would be a
powerful feature learning model for high dimensional classification problems.
However, for the problem of knowledge discovery, it is hard to interpret which
subsets of genes were responsible for deriving such predictions. To overcome
the inherent issue of poor explanatory power associated with the deep learn-
ing paradigm, a new weight interpretation method is presented that aids the
researcher in opening up the so-called black box of the network to ascertain
which genes were dominant within its internal representations. The proposed
weight interpretation method will also aid researchers in bioinformatics to
discover important biomarkers from the newly discovered representations of
such DL models. A model that is able to state which phenotypes are key
factors is a crucial element of prediction systems used by health practitioners
and decision-making professionals. It is therefore very important we are able
to provide some explanatory capability to our deep feature learning model.
The paper is structured as follows: Section 2 discusses the fundamental
concepts of deep learning methods and provides relevant current state-of-the-
art research of employing deep learning models for solving different problem
domains, including the knowledge extraction from omics data; Section 3
introduces the framework for deep feature learning model proposed for the
extraction of knowledge from HDSSS datasets in a way that is transparent
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and supports the endeavour of precision medicine; Section 4 proposes a new
weight interpretation method called Deep Mining for opening the black-box
of such deep learning models and reveal key determinants underlying its
latent representation to aid feature selection; Section 5 explains the datasets
used to perform omics data modelling and analysis and the experimental
methodologies and evaluation metrics applied to estimate the robustness of
the discovered biomarkers; Section 6 presents and discusses the obtained
outcomes of our experiments. A conclusion is introduced in Section 7.
2. Deep Learning for Biomarker Discovery
In the neural network literature, the emphasis has been made on the com-
position of multiple levels of nonlinearity and the transformation of the input
signal from low-level features into high-level abstractions [9, 10]. This type
of automated deep feature learning has provided superior performance over
traditional learning approaches by handling the curse of dimensionality, im-
proving the generalisability, and making meaningful use of the data in a wide
range of problem domains. Deep learning (DL) can be defined as deep feature
learning methods that consist of multiple layers of non-linear functions that
are connected in a hierarchical fashion, where the output values of the units
in one layer feed as input into a unit in the next or preceding layers so that
complex functions can be constructed using the well-known stochastic gra-
dient descent algorithm, back-propagation [11]. These automated learning
algorithms have been incorporated in diverse areas of Bioinformatics (e.g.
[12, 13, 14, 15, 16]). Furthermore, the deep neural network models have
been applied across different problem domains in healthcare area like clinical
imaging (e.g. [17, 18, 19, 20]), electronic health record (e.g. [21, 22, 23]),
wearable sensor (e.g. [24, 25, 26]). Moreover, DL models have provided a su-
perior performance over traditional methods in a wide range of domains such
as computer vision (e.g. [27, 28]), natural language processing (e.g. [29, 30]),
speech recognition (e.g. [31, 32, 33]), and remote sensing (e.g. [34, 35]).
In many of these problem domains, a large number of samples are typically
available to train a deep network model where the signal-to-noise ratio is
quite high. The key challenge is to capture generic factors of variations that
underlie the unknown structure of the data in a way that can significantly
enhance the generalisation to unseen observations. This is, however, not the
case in bioinformatics research where high-throughput biomedical datasets
are characterised by a relatively small number of biological samples, which
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in turn have a low signal-to-noise ratio. Therefore, for omics data analysis,
the problem is more likely to be that the number of variations underlying the
data is not adequately exploited due to an insufficient number of biological
samples. As a result, it may seem somewhat counterintuitive to use deep
neural network models for HDSSS datasets, as found in omics data, due to the
fact that these learning models typically require substantial data to constrain
their parameters and learn a useful hypothesis. Applications of deep neural
network methods for knowledge discovery from HDSSS omics data remain
scarce. This necessities further investigations for the goal of introducing
new deep learning-inspired paradigms that can approximate enough of the
relevant variations represented by those biological samples.
The most popular form of DL is the supervised learning approach where
the desired response of the system is known during the learning process.
When the desired outcomes are known, the learning process relies on fitting
the model to reduce the distance between the desired outcomes and the actual
outputs and thus to adjust the internal parameters to shorten that distance
according to some cost function (e.g. sum of the squared errors or log likeli-
hood). Supervised learning procedures do not typically allow for self-taught
learning where the model is free to identify and exploit more subtle patterns
in high dimensional spaces [36]. Therefore, the proposed deep feature learn-
ing model is trained using the unsupervised pre-training approach in order
to exploit the unknown structure of HDSSS omics data for identifying ro-
bust genomic or proteomic patterns that can differentiate the patients with
cancer from those without cancer effectively. The unsupervised pre-training
approach presented by renown researchers in 2006 to advance the traditional
method of training DL models: Restricted Boltzmann Machines (RBMs) [37]
by Geoffrey Hinton, Auto-Encoder Variants [38] by Yoshua Bengio, Sparse
Coding Variants [39] by Yann LeCun. The unsupervised pre-training ap-
proach is based on very interesting notions. Mainly, a deep neural network
model can be learned based on the unsupervised pre-training hidden layer by
hidden layer ‘sequentially’, where within each layer, the network attempts to
discover a useful representation of its input (which may be a previous hidden
layer of activations). This greedy recursive approach to transforming the data
starting from the input layer, to form a hidden layer, which is then provided
as input to a process to form another hidden layer provides a powerful means
to alleviate against the curse of dimensionality and create high-level abstract
representations from detailed low-level representations. Moreover, previously
learned knowledge by the greedy layer-wise approach can be passed as input
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to a supervised classifier model, such as an SVM or perceptron. That means,
the learning task can be conducted using a semi-supervised approach, with
the goal of learning to discover a good representation that shapes the input
distribution, which is also relevant in part to discover the response group.
Therefore, the discovered features by the DL models can be shared between
tasks. The identification of relevant invariant features that makes sense for
several tasks is a highly desirable property to approach Artificial Intelligence
(AI).
As a result, our feature learning model is introduced based on multiple
levels of unsupervised learning constructed on sparse under-complete repre-
sentations of increasing complexity to forces the neural network to discover
meaningful aspects of the training samples that resemble the salient features
necessary to fully recover the data. These types of abstract expressive rep-
resentations have the potential to distil the high-level and invariant signals
from the noise effectively making them highly non-linear functions of the
input.
2.1. Interpretation Methods for Deep Learning
The latent representations discovered by such deep learning methods that
are resulted from multiple levels of input transformation are combinations
of the original features, different and more likely smaller. Therefore, for a
biomarker discovery problem, it is hard to recognise which subsets of genes
constituted these abstract representations and were responsible for playing
a significant role in deriving such predictions. In addition to knowledge dis-
covery, the identification of a robust set of molecular markers can boost the
explainability of diagnosis and prognosis systems and contribute to develop-
ing a reliable and trustable prediction model that can be employed in clin-
ical practice. Furthermore, stating which phenotypes underlie the variation
of cancer and control groups increases the certainty in the decision-making
process. However, the difficulty of deconstructing DL methods remains a
major obstacle for employing these advance feature learning techniques in
omics data analysis for the goal of biomarker identification.
In the literature, few attempts have investigated going beyond the pre-
diction to understand the machinery of such DL models and interpret its
outcomes. Tan et al. in [40] and later in [41] have examined the significance
of each neuron by computing its activity value in a single layer Auto-encoder
and for each sample. Such models are considered shallow Auto-Encoder mod-
els as they typically only contain one hidden layer in-between the input and
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output layer. For example, the shallow network in [40] contains 100 hidden
neurons and [41] auto-Encoder contains 50 hidden neurons in order to allow
the manual interpretation of these nodes, which cannot be generalised to the
deep network models with higher capacities. More complex hierarchical rep-
resentations can be formed by recursively autoencoding the hidden layer of
the original shallow autoencoder - this is known as stacking the autoencoder.
Danaee et al. [42] map back the lower dimensional representations of the
Stacked Denoising Autoencoder (SDAE) to the original data to detect what
they called Deeply Connected Genes (DCGs). The interpretation method
of SDAE results in a 500 × G matrix, where G is the number of genes in
the gene expression data and 500 seems to be the code dimension - (i.e the
hidden layer with the lowest number of dimensions). The authors state that
genes with the largest weights in the detected matrix are the DCGs. How-
ever, it is not clear how they defined the DCGs especially when each gene
has 500 values and there is no evidence whether they have considered the
largest weights in the positive or the negative direction.
In this research project, a new interpretation method called deep mining
is introduced to decode the mechanism of the proposed deep feature learning
model so that a reduced set of highly predictive and reliable biomarkers can
be derived effectively.
3. Deep Feature Learning Model
A new deep feature learning model called a Stacked Sparse Compressed
Auto-Encoder is proposed in this paper to infer useful knowledge from HDSSS
omics data for modelling reliable prediction systems. The Stacked Sparse
Compressed Auto-Encoder is utilised to mitigate against the sparsity of the
data in these large spaces in which it reduces the number of samples required
to discover relevant variations underlying high throughput omics datasets.
Furthermore, it endeavours to promote the notion that different aspects are
characterised by different features so that a small set of different groups of
hidden neurons allocated to different subsets of features. As a result, a small
proportion of potentially relevant and insensitive determinants is utilised to
represent various inputs through multiple levels of the deep feature learn-
ing model. Consequently, the learning process proceeds successfully using
the available samples addressing the problem of high dimensionality, small
sample sizes and signal-to-noise ratios of omics data. Furthermore, training
the deep neural network model based on sparse compressed representations
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of increasing complexity contributes to employing a less number of hidden
neurons and a small fraction of parameters. Therefore, the computational
and statistical challenges arising from handling the large and noisy spaces
of genomic and proteomic data are tackled, and a high level of efficiency is
achieved.
3.1. Auto-Encoder
An Auto-Encoder (AE) is a neural network model that is trained to map
an input x into a code representation y using an encoding function f , where
g is a decoding function that transforms y to construct z as closely as possi-
ble to x (thus modelling the identity function). The encoder is a non-linear
sigmoid function s that transforms the input vector x into the hidden rep-
resentation y, which is expressed as fθ(x) = s(Wx + b) with parameters
θ = {W, b}. The weight matrix W is d′ × d, where d corresponds to the
dimension of x and d′ corresponds to the dimension of y, and b is an bias
vector of dimensionality d′. The decoder is a non-linear sigmoid function, s,
that transforms back the hidden representation y to construct the vector z of
dimensional d, which is expressed as z = gθ(y), where gθ(y) = s(W
′y + b′)
with the parameters θ′ = {W ′, b′}. The learning process relies on finding the
parameters θ that significantly minimise the cost function, which measures
the discrepancy between the original data x and its reconstruction z.
3.2. Sparse Compressed Auto-Encoder
A Sparse Compressed Auto-Encoder (SCAE) is an AE that adds spar-
sity penalty to the compressed representations to capture distinctive generic
features from HDSSS data. Sparsity refers to render the units of hidden
layers to be at or near zero so that most factors become irrelevant and few
are relevant and insensitive to irrelevant variations. Under-complete or com-
pressed representations corresponds to that the code dimensions (i.e. code
refers to the hidden layer with the lowest number of dimensions that captures
the most abstract features encoded) tend to be smaller than input dimen-
sions. For the SCAE, z is not supposed to be an exact reconstruction of
x, but rather it is meant to be a rough approximation (within an allowable
error tolerance) that is less sensitive to variations from the training data
leading to avoid the risk of overfitting where very low bias and high vari-
ance might be obtained. Moreover, generating a rough approximation will
force the network to learn some kind of meaningful relationships between
variables. Furthermore, placing constraints on the compressed AE leads to
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activate hidden neurons in response to given input contributing to distilling
effectively enough of the interesting complexity underlying the representative
samples that can approximate the input distribution.
Let ρˆi =
1
n
∑n
j=1 aixj be the activation of hidden neuron i over a collection
of training examples. Neuron i is considered active if the average activation
value over all the training examples is close to 1, or inactive if the average
value over all the training examples is close to 0. Enforcing the constraint
ρˆi = ρ, where ρ is the sparsity parameter, which takes a small values close to
zero (e.g. ρ = 0.05). As explained previously, a low activation value means
that the hidden neuron reacts to a small number of the training examples,
which means different sets of hidden neurons assigned to different statistical
features. These patterns of activation can be statistically more efficient since
a large number of possible sets of features can be activated in response to
given input. Therefore, a regulariser is added to the cost function to enforce
the values of ρˆi to be low as follows:
Ωsparsity =
d′∑
i=1
ρ log(
ρ
ρˆi
) + (1− ρ) log( 1− ρ
1− ρˆi ) (1)
In order to reduce the magnitude of the weights and avoid the risk of over-
fitting so that the learned representations rely on the input features rather
than the deep network structure, L2 regularisation term on the weights is
added to the cost function as follows:
Ωweights =
1
2
L∑
l
n∑
j
k∑
i
(W lji)
2 (2)
where L is the number of hidden layers, n is the number of examples, and
k is the number of variables. The cost function of training the SCAE is a
mean squared error (MSE) function, which is formulated as follows:
MSE =
1
N
N∑
n=1
K∑
k=1
(xkn − zkn)2 + λ× Ωweights + β × Ωsparsity (3)
where λ controls the impact of the weight regulariser in the cost function, and
β controls the impact of the sparsity regulariser in the cost function. When
handling high dimensional datasets, the optimisation techniques should be
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applicable to these large-scaled problems. Several studies [43, 44, 45, 46]
have shown the feasibility of the Scaled Conjugate Gradient descent (SCG)
method to handle such problems in an effective way. Therefore, the SCAE
is trained with SCG backpropagation method [47].
3.3. Stacked Sparse Compressed Auto-Encoder
The Stacked Sparse Compressed Auto-Encoder (SSCAE) can be devel-
oped using a series of SCAEs. The encoding procedure of the SSCAE that
has L layers can be expressed as follows: y = fl(...fi(...f1(x))), where fi is
the encoding function of the module i, while the decoding procedure can be
defined as: z = gl(...gi(...g1(y))), where gi is the decoding function of the
level i. The intensity values of mass spectrometry data and the expression
values of mRNA samples were represented in the input layer to be trans-
formed into high-level features of increasing abstractions by the last layer.
A series of cross validation experiments were conducted to assess the per-
formance of the selected models and identify the best performing one based
on the validation performance. Therefore, the SSCAE is designed with four
layers of dimensions 500, 200, 100, 50 so that the key complexity of the in-
put distribution represented by the biological samples is modeled effectively.
Then, the 50 dimensional feature vectors are employed to train the softmax
classification layer for forcing the output of the SSCAE to sum to 1, thus
forcing backpropagation to be aware of the whole output layer. The SCG
method [47] is also employed to optimise the learning process of the SoftMax
neural network layer that is trained in a supervised fashion based on the
Cross-Entropy (CE) function:
CE =
1
n
n∑
j=1
k∑
i=1
tij ln yij + (1− tij) ln(1− yij) (4)
where n is the total number of the training examples, k is the number of the
response groups, tij is the ijth element of the response group matrix, which
is k × n matrix, and yij is the ith output from the SCAE when the input
vector is xj. The response groups of the utilised datasets were represented
in the output layer coded as 0 for Normal and 1 for Cancer for ovarian can-
cer dataset. For METABRIC dataset with Estrogen Receptor, the response
groups were encoded in the output layer as 0 for Negative Estrogen Receptor
(ER-) and 1 for Positive Estrogen Receptor (ER+). For METABRIC dataset
with Progesterone Receptor, the response groups were encoded in the output
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layer as 0 for Negative Progesterone Receptor (PR-) and 1 for Positive Pro-
gesterone Receptor (PR+). The SSCAE is trained in a supervised fashion
based on the CE function of Equation 4 and the SCG optimisation method
using the full training set and then it is validated using the full correspond-
ing validation set. To account for variance in the performance estimation,
the SSCAE is trained using variant sets of training samples and the average
predictive performance is reported. Furthermore, the performance of each
trained SCAE module is examined using the MSE between the validation set
and its reconstruction, which is predicted by the SCAE that was trained on
the corresponding training set.
The capability to form deep feature hierarchies by stacking the unsuper-
vised modules with the SoftMax classifier results in forming highly abstract
molecules that preserve the key determinants within the original data. How-
ever, it is hard to understand which genes were dominant within the latent
representations of the SSCAE, which is the aim of omics data analysis study.
We now propose a new technique called deep mining to sculpt inside the SS-
CAE in order to deconstruct its internal state for biomarker identification.
4. Deep Mining: A New Weight Interpretation Method
Several hypotheses that have been proposed in the literature to justify
why learning based on the unsupervised pre-training approach works well
have highlighted the importance of finding the appropriate weights in guiding
the learning process towards discovering a good representation similar to the
optimisation [11] and regularisation [7] hypotheses. The learning process of
DL models can be described as fitting weight parameters in a way that can
significantly minimise the loss function. For a shallow AE, the weight of each
variable reflects its contribution on the node’s activity so that the signal with
a larger weight has a greater impact. However, given the deep architecture
of the SSCAE model, how can we quantify the contribution of each feature?
When the SSCAE model is constructed on the training set, the classification
error is back-propagated through the layers of the SSCAE to the input layer
to estimate the individual contribution of each variable. That means, the
impact of each variable on the classification accuracy is forward-propagated
from the input layer through the layers of the Deep network. Since the
weight is the main indicator of variable’s importance, the relevancy of each
feature can be detected through leveraging the Input Weight matrix (IW)
of the SSCAE with its Layers Weight (LWs) matrices. As a result, the
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Figure 1: Histogram of z-scores of the weight vector.
integrated impact of each gene in the data over the depth of the SSCAE can
be formulated as follows:
DM = IW>
L∏
i=1
LW>i . (5)
which results in a d × 1 weight vector called DM, where d corresponds to
the number of features in the original datasets so that each feature has a
weight score that reflects its contribution. The weight vector DM resembles
a normal distribution as shown in Figure 1 of ovarian cancer dataset at fold 1
of the cross validation procedure. A small percentage of features in the DM
exhibit High Positive (HP) or High Negative (HN) weight as shown in Figure
1. Two lists of features with a length of the bottleneck code (i.e. 50): 1) with
HP weight and 2) with HN weight are detected from DM. To examine the
consistency of feature selection of the proposed SSCAE over variant training
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datasets, k weight vectors DMs are obtained over cross validation iterations,
thus k lists of genes with HP weights and k lists of genes with HN weights
are generated. The positive lists are compared to find the most frequently
selected predictors with HP weight and the negative lists are examined to
identify the most consistently detected predictors with HN weight.
5. Experimental Methodology
This section focuses on the datasets and the experimental methodolo-
gies used for model fitting and selection and therefore to validate the out-
comes of the proposed SSCAE together with the deep mining model. The
datasets used for the evaluation are initially described followed by experimen-
tal methodologies adopted, including the applied validation and evaluation
metrics.
5.1. Dataset
The development of the breakthroughs for extracting useful knowledge
from high-throughput omics data is at the core of personalised and precision
medicine. However, we are able to benefit from these biological data only
if they are publicly available. Recently, there is increasing pressure from
funding providers and the patient community to gain the maximum benefit
from produced data by sharing it with the research community regardless
whether biomedical studies are funded publicly or privately [48]. Analysing
omics data over several research studies can help to control the risk of false
positives, offer possibilities to innovative discoveries, and to report signif-
icant and reliable findings [49]. Therefore, two publicly available HDSSS
Mass Spectrometry and Microarray datasets are used for the experimental
evaluation. They are:
• Ovarian Cancer. This dataset is publicly available on the FDA-NCI
Clinical Proteomics Program Databank website1. The high-resolution
ovarian cancer dataset was generated using the WCX2 protein array to
identify serum (blood-derived) proteomic patterns that differentiate the
serum of patients with ovarian cancer from that of women without ovar-
ian cancer. It contains 216 samples and 15000 features. Each patient
sample has one of the response groups: Normal or Cancer, 121(56%)
1https://home.ccr.cancer.gov/ncifdaproteomics/ppatterns.asp
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observations are derived from cancer patients, where 95(44%) obser-
vations are from the normal group. The features of Mass Spectrome-
try data represent the ion-intensity levels of the patients at particular
mass-charge value.
• METABRIC Breast Cancer. This dataset [50] was generated from
METABRIC [51, 52] and downloaded from cBioPortal [53]. The cancer
study identifier is (brca metabric), and the name is (METABRIC, Na-
ture 2012 & Nat Commun2016). Two response groups that are iden-
tified in this research are the status of Estrogen Receptor (ER) and
Progesterone Receptor (PR). If breast cancer cells have high ER, the
cancer is described as ER-positive (ER+), and if breast cancer cells
have high PR, the disease is specified as PR-positive (PR+) cancer.
ER and PR expressions have been utilised as robust indicators for the
evaluation of breast cancer. All newly diagnosed invasive breast cancer
patients and breast cancer recurrences should be examined for both ER
and PR according to the recommendations of the American Society of
Clinical Oncology and the College of American Pathologists [54]. How-
ever, it has been shown that the expression of ER and PR receptors
changes during the development of breast cancer and in response to
systemic therapies [55]. Several expression profiling studies have illus-
trated that the expression of hormone receptors is linked with diverse
genetic variations [56, 57, 58]. That means several mutated genes can
affect the development and progression of breast cancer and contribute
to its heterogeneity [59]. As a result, investigating molecular charac-
teristics of the tumours that could act as risk factors of breast cancer
is considered a serious aetiologic question [60]. This research project
aims to identify key genes that underlie the biological processes of ER
and PR receptors.
METABRIC dataset contains diverse biomedical modalities including
clinical data and two genomic datasets: gene expression, and copy
number alterations. The focus of this research is on mRNA expression
dataset that was carried out using Illumina Human v3 microarray and
contains 24368 genes and 1904 samples as shown in Figure 2. The in-
tegration between mRNA expression dataset and ER clinical attribute,
which has 1980 cases generated a dataset of 1904, 1459(76.63%) tu-
mours were derived from patients with ER+, and 445(23.37%) tumours
were derived from ER- samples. Where the unification between mRNA
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Figure 2: The description of (METABRIC) dataset showing the unification between clin-
ical data and mRNA expression data.
expression dataset and PR clinical data that contains 1980 observations
resulted in a dataset of 1904 cases. The number of observations with
PR- is 895, so the percentage of PR-negatives is 47.01%, comparing to
1009(52.99%) observations came from patients with PR+ tumours.
Gene expression datasets typically contain thousands of genes, not all
of these information are relevant. In the microarray literature, several
studies have revealed the potential of filtering out genomic datasets
from genes with unreliable measurements to enhance the detection of
differentially expressed genes [61, 62, 63, 64]. Genes that seem to gen-
erate uninformative signals can be considered as noise. A gene with
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small profile variance across the samples would not differ significantly
among response groups, thus genes with a variance less than the 10th
percentile were removed from the analysis in this research. Further-
more, gene expression datasets could have genes whose range of values
may not well distributed. Therefore, genes with low entropy expres-
sion values (i.e less than the 10th percentile) were removed from the
analysis in this research. A more detailed discussion of these rudimen-
tary filtering methods can be found in [65]. After eliminating the least
promising genes from the analysis, the number of remaining features of
both response groups ER and PR is 19732 gene profiles as illustrated in
Figure 2. This figure provides a summary of the number of samples and
genes of mRNA expression dataset before and after the pre-processing
step.
5.2. Experimental Methodology
The aim of proposing the SSCAE together with the weight interpretation
method is to derive cancer markers whose behaviour differs across conditions,
thus they can be used to model reliable prediction systems. Consequently,
the generalisability of a machine learning model built on a dataset contain-
ing only the informative genes is employed. For small cancer datasets, two
powerful but not so adaptable classification models are utilised, which are
Support Vector Machine (SVM) [66], and Bagging Decision Tree (BDT) [67]
to evaluate the quality of the discovered biomarkers. These learning tech-
niques are selected due to their empirical power and success in the same or
similar domains. Generalisability of classification models can be defined as
its ability to correctly estimate the response groups of unobserved sample
cases – (that were not included in the training data). The Area Under the
Curve (AUC) of the Receiver Operating Characteristics (ROC) is utilised
for estimating the predictive performance of the learning methods. AUC is
more reliable than accuracy and more discriminative than other estimation
measures and can be measured over the range of TPR and FPR [68, 69].
AUC resides in the range of [0, 1] if the AUC value is equal to 1, it means
the predictive performance is perfect (i.e. the classification model correctly
assigned all the unseen new cases). If AUC = 0.5 refers to classification by
chance (random guessing), and AUC = 0 refers to an inverted perfect clas-
sification. In this work, the AUC metric measures the overall quality of the
prediction systems with 0.99 confidence level.
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Estimation of the predictive performance of learning models is an essen-
tial step, since it guides the process of model selection, and evaluates the
goodness of the chosen model. For model selection and evaluation, a re-
peated 5-fold cross validation procedure is utilised. The 5−fold CV method
is empirically established due to achieving a good compromise when at-
tempting to address the Bias-Variance trade-off for small cancer datasets.
Each dataset is partitioned into 5 non-overlapping subsets of equal size
P = {p1, p2, , p3, p4, p5}. The data subsets are stratified so that each fold con-
tains approximately the same proportions of response groups as in the origi-
nal data, and there is evidence that this can enhance the estimation process
[70]. The SSCAE is repeated 5 iterations, at each iteration i ∈ {1, 2, 3, 4, 5},
the SSCAE is applied on P \ pi. Over iterations, a set of subsets of fea-
tures FS = {fs1, fs2, fs3, fs4, fs5} is produced. When FS is obtained, the
consistency of feature preferences of the proposed SSCAE is examined by
comparing the subsets of features in FS to define the most frequently se-
lected features. The consistency of selection is more likely correlated with
the predictive power of features so that the most consistency selected fea-
tures should be most relevant, whereas the least consistency selected features
should be less relevant.
6. Results and Discussion
This section evaluates the performance of the proposed SSCAE and deep
mining model applied to ovarian and METABRIC breast cancer datasets.
Initially, the stratified 5−fold cross validation procedure was utilised to divide
each dataset randomly into training sets and validation sets as shown in Table
1. At each iteration, the SSCAE model was trained using the training set
and validated using the corresponding validation set as shown in Figure 3 -
represented by the confusion matrices and the ROC curve plots for the final
iteration. The average predictive performance of that deep feature learning
model quantified by AUC is shown in Table 2.
Table 1: The sizes of the training-validation sets of ovarian and METABRIC datasets
Dataset Training Sets Validation sets
Ovarian Cancer [173, 172, 173, 173, 173] [43, 44, 43, 43, 43]
METABRIC [1524 1523 1523 1523 1523] [380, 381, 381, 381, 381]
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Figure 3: The validation performance of the SSCAE at the final iteration for ovarian
cancer, METABRIC with ER groups, and METABRIC with PR groups.
The outcomes of our experiments reveal that the SSCAE was able to
learn highly abstract and invariant features from cancer datasets, and thus
highly accurate and reliable prediction models were formed. Furthermore,
the performance of each trained SCAE module was examined at each cross
validation iteration using the MSE between the validation set and its re-
construction, which was predicted by the SCAE that was trained on the
corresponding training set. Over iterations, the average performance of each
SCAE quantified by the MSE is shown in Table 3.
Table 2: The average performance of the SSCAE of ovarian and METABRIC datasets.
Dataset AUC
Ovarian Cancer 0.9843
METABRIC with ER 0.9884
METABRIC with PR 0.9380
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Table 3: The average MSE of each SCAE of ovarian cancer and METABRIC datasets.
Dataset SCAE1 SCAE2 SCAE3 SCAE4
Ovarian Cancer 0.0016 0.0010 0.0024 0.0024
METABRIC with ER 0.0356 0.0130 0.0074 0.0037
METABRIC with PR 0.0373 0.0125 0.0079 0.0036
Simultaneously, the proposed deep mining model was applied at each
iteration to define two lists of features with HP and HN weight. Over the
cross validation iterations, the five identified groups of features with HP
weight were compared to provide a subset of stable predictors and by the
same way, a subset of stable predictors with HN weight was produced. The
experimental results of applying the ensemble deep mining model to ovarian
cancer dataset will be discussed first in the following section followed by the
outcomes of METABRIC breast cancer dataset with ER and PR groups.
6.1. Results of Ovarian Cancer Dataset
The examination of the ten obtained lists of candidate features of ovarian
cancer dataset resulted in finding 6 robust biomarkers with HP weight as
shown in the matrix of scatter plots of these biomarkers in Figure 4. The
biomarkers were plotted in X-axis and Y-axis ascendingly using their index
as illustrated in Figure 4. It can be observed from this figure that the in-
tensity distributions of the proteins with HP weight differ significantly for
the cancer patients from those from the normal group. Moreover, 13 robust
biomarkers were detected from comparing the identified groups of candidate
proteins with HN weight as shown in Figure 5. As mentioned previously, the
biomarkers were plotted in X-axis and Y-axis ascendingly using their index.
It can also be observed from this figure that the intensity distributions of
the proteins with HN weight for the observations in the cancer group differ
significantly from those in the normal group. Typical biomarkers identifi-
cation models adopt the principle that the expression levels of genes or the
intensity values of proteins that exhibit the greatest variations across the
differentiated groups can be considered as potential biomarkers for a disease
or clinically relevant outcome. Therefore, the detected proteins with HP and
HN weight could act as potential biomarkers for ovarian cancer.
The discovered subsets of robust biomarkers with HP and HN weight
were utilised individually and collectively to develop prediction models using
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Figure 4: Scatter plots matrix of the discovered biomarkers (index) with HP weight of
ovarian cancer dataset.
the SVM and BDT classifiers. The average predictive performance of both
classification models is presented in Table 4. The outcomes of our experiment
show that the ensemble subset of HP and HN weighted proteins (i.e. All)
contributed to constructing highly accurate and reliable prediction systems.
Table 4: The average performance of the SVM and ENS models built on the subsets of
biomarkers of ovarian cancer dataset.
The subset of SVM BDT
HP biomarkers 0.8886 0.8726
HN biomarkers 0.8975 0.8828
All biomarkers 0.9227 0.8964
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Figure 5: Scatter plots matrix of the discovered biomarkers (index) with HN weight of
ovarian cancer dataset.
Our findings demonstrate first the efficiency of the proposed SSCAE to
capture intrinsic structure in serum (blood)-derived proteomic data. Sec-
ondly, it is a strong indicator that the proposed deep mining model was able
to deconstruct the SSCAE and interpret its weight matrices effectively so
that the proteomic patterns that can differentiate the patients with ovarian
cancer from the women without ovarian cancer were detected in two forms.
6.2. Results of METABRIC Breast Cancer Dataset
This section evaluates the performance of the proposed deep mining model
applied to analyse the weight matrices of the SSCAE built on METABRIC
dataset with ER and PR groups for the goal of discovering robust biomarkers
that are positively and negatively associated with the hormone receptors.
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Figure 6: Scatter plots matrix of the discovered biomarkers with HN weight of METABRIC
dataset with ER groups.
6.2.1. Results of ER Groups
The application of the ensemble deep mining model to METABRIC dataset
with ER groups resulted in defining 25 robust biomarkers with HP weight as
shown in Figure 7. Furthermore, 7 robust biomarkers were detected from the
identified subsets of candidate genes with HN weight as shown in Figure 6.
The mRNA markers were plotted in X-axis and Y-axis alphabetically using
their names as shown in Figures 6 and 7. It can be observed in both figures
that the expression levels of the recognised genes for the patient with ER+
tumours differ significantly from the samples with ER- tumours. Therefore,
the detected mRNA markers with HP and HN weight could act as potential
biomarkers for breast cancer and ER positivity.
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Figure 8: Scatter plots matrix of the discovered biomarkers with HP weight of METABRIC
dataset with PR groups.
6.2.2. Results of PR Group
The application of the ensemble deep mining model to METABRIC data
with PR groups led to identifying 6 robust biomarkers with HP weight as
shown in Figure 8. Furthermore, 5 mRNA markers were found to be neg-
atively associated with PR positivity as shown in Figure 9. The discov-
ered mRNAs were plotted in X-axis and Y-axis alphabetically using their
names as illustrated in Figures 8 and 9. As shown clearly in these figures,
the mRNA markers exhibit distinct expression levels for the patient with
PR+ tumours from the samples with PR-negative tumours. Therefore, the
discovered mRNA markers with HP and HN weight could act as potential
biomarkers for breast cancer and high PR level.
The subsets of the discovered biomarkers were used to build prediction
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Figure 9: Scatter plots matrix of the discovered biomarkers with HN weight of METABRIC
dataset with PR groups.
models individually and as an ensemble using the SVM and BDT methods.
The average predictive performance of both classifiers is presented in Table 5.
For ER groups, the outcomes of our experiment reveal that the HP weighted
biomarkers of METABRIC dataset built highly accurate and robust classi-
fication models than HN weighted genes. Furthermore, the integration of
the subsets of mRNA markers has improved the predictive performance of
the SVM model only and very slightly. Similar findings were also obtained
from the METABRIC dataset with PR groups where the predictive perfor-
mance of the classification models built on the HP weighted biomarkers is
significantly higher than its performance when trained using mRNAs with
HN weight. Moreover, the ensemble subset of the discovered biomarkers has
improved the performance of the BDT model only and very slightly.
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Table 5: The average performance of the SVM and ENS models built on the subsets of
biomarkers of METABRIC datasets.
The subset of SVM BDT
HP biomarkers with ER 0.9820 0.9853
HN biomarkers with ER 0.9023 0.8838
All biomarkers with ER 0.9855 0.9850
HP biomarkers with PR 0.9825 0.9815
HN biomarkers with PR 0.7290 0.7143
All biomarkers with PR 0.9815 0.9824
6.3. Discussion
The outcomes of our experiments for ovarian cancer dataset have shown
how the intensity values of the detected proteins with HP weight differ signif-
icantly from the intensity values of the discovered proteins with HN weight
for the cancer and normal samples. More specifically, the intensity values of
the selected proteins with HP weight for the patients who suffer from cancer
are more likely to be higher than most of the normal samples as shown in
Figure 4. Contrary to the intensity distributions of the discovered proteins
with HN weight, where their intensity values for the normal observations are
more likely to be higher than most of the cancer samples as illustrated in
Figure 5. Firstly, this is strong evidence that validates the effectiveness of
the SSCAE to capture the interesting complexity in serum (blood)-derived
proteomic data. Secondly, it is a strong indicator that demonstrates the ca-
pability of the proposed deep mining model to deconstruct the internal state
of the SSCAE effectively so that the salient and robust proteomic signals that
are positively and negatively associated with ovarian cancer were discovered
robustly.
The experimental results of METABRIC dataset with ER groups have
shown how the expression levels of the discovered genes with HP weight differ
significantly from the expression levels of the HN weighted mRNA markers
for ER+ and ER- samples. More specifically, our findings reveal that the
expression levels of HP weighted mRNA markers are more likely to be higher
for the patients with ER+ tumours compared to most of the ER-negatives
as shown in Figure 7. In contrast, the identified mRNAs with HN weight
exhibit higher expression levels for the observations from the ER- group in
comparison to the ER-positive patients as shown in Figure 6. This provides
27
another great evidence that verifies the efficacy of the proposed SSCAE to
discover useful knowledge from this HDSSS genomic data as well as the
potential of the deep mining model to interpret the weight matrices of the
SSCAE and recognise robust biomarkers that are positively and negatively
associated with breast cancer and ER positivity.
The experimental outcomes of METABRIC dataset with PR groups have
explained the significant differences in the expression levels of the discovered
biomarkers with HP weight from the HN weighted mRNAs for PR+ and
PR- samples. It has been shown in this research that the patients with
PR+ tumours are more likely characterised with high expression levels of
the selected mRNAs with HP weight compared to the samples from the PR-
group as presented in Figure 8. In contrast, mRNA markers with HN weight
exhibit low expression levels for patients with PR+ tumours in comparison to
most of the PR- samples as explained in Figure 9. This is a strong indicator
that verifies the capability of the SSCAE to learn high-level abstract features
from this HDSSS genomic dataset. Moreover, this is significant evidence that
supports the validity of the presented deep mining model to open the black
box of that deep feature learning model and discover interesting patterns
that are associated with breast cancer and high PR levels positively and
negatively.
Our findings reveal conclusive evidence of a positive or a negative asso-
ciation between each single biomarker and its response group. The positive
association was observed between the discovered genes or proteins with HP
weight and the positive response group (i.e. Cancer, ER+, PR+) as shown
in Figures 4, 7, 8. The positive correlation corresponds to the gains in the
expression/intensity levels of these biomarkers and its contribution to cancer-
ous of ovarian or ER/PR positivity. The inverse correlation was recognised
between the identified genes or proteins with HN weight and the positive
response group (i.e. Cancer, ER+, PR+) as shown in Figures 5, 6, 9. The
negative correlation refers to the declines in the expression/intensity levels
of these biomarkers and its contribution to ovarian cancer and ER/PR posi-
tivity. This provides very strong evidence that validates the potential of our
deep mining model to interpret the weight matrices of the SSCAE by finding
generic features that exhibit HP and HN weight scores. In addition, this
also reflects the capability of the SSCAE in assigning correctly HP weight to
the biomarkers that are highly expressed for the positive patients compared
to the negative samples, and HN weight to the biomarkers that are lowly
expressed for the positive patients in comparison to the negatives.
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Our computational study that aims for knowledge discovery from omics
data focuses mainly on data modelling, analysis, and validation that allow
new sets of biomarkers for ovarian and breast cancers to be discovered effi-
ciently and validated reliably. The discovered molecular markers could an-
swer different biological questions of interest and contribute to developing
more personalised treatment or monitoring planning by investigating further
the mechanism underlying the association of expression patterns of these
biomarkers and the cancers of interest. Our novel deep mining model pro-
vides yet another arrow within the quiver of bioinformaticians for discovering
and evaluating new biomarkers that may help further the endeavor of pro-
ducing more effective and personalised medicine.
7. Conclusions
The process of inferring useful knowledge from HDSSS omics data poses
several critical issues that arise due to experimental, statistical and compu-
tational challenges. The limitations of existing approaches established by
the literature review drive us to critically assess the usefulness of deep neural
network methods for the problem of knowledge discovery from high through-
put omics data. The critical evaluation has resulted in defining the key
requirements for a deep feature learning model to be able to capture enough
of the important variations underlying the representative biological samples.
Consequently, we introduce the proposal of the SSCAE for the extraction
and analysis of reliable knowledge from human molecular data for modelling
robust prediction systems.
The deep mining model is proposed to open the black-box of the SSCAE
and find robustly which genes were dominant within its internal represen-
tations. The detailed evaluation of the deep mining model demonstrates its
capacity to recognise the biomarkers that exhibit HP or HN weight scores
over the depth of the network. HP weighted biomarkers are the molecules
that have a strong positive correlation with the positive group, where HN
weighted biomarkers are the molecules that have an inverse association with
the positive group. This explains the internal mechanism of the SSCAE in
assigning HP weight to the features that are highly expressed for the posi-
tives in comparison to most of the negatives. In contrast, HN weights were
allocated by the SSCAE to the features that are lowly expressed for most of
the positives in comparison to the negatives. The validation process reveal
that the discovered biomarkers demonstrate computational and biological
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relevance as well as the capability to construct highly accurate and reliable
prediction models. This provides significant evidence that the deep mining
model was very effective in offering explainability to the deep learning model
and detecting key determinants underlying its latent representations.
In the next publication, the capacity of the proposed deep feature min-
ing model to detect generic biomarkers for breast cancer from a wide range
of independently generated cancer genomic samples that are collected from
completely different studies is investigated so that the highest evidence that
a tool validates can be provided. As mentioned previously, our deep min-
ing model is problem-independent and data-driven, thus, it provides further
potential for this research to extend beyond its cognate disciplines.
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